India Molecular Diagnostics Market Size, Share & Trends Analysis Report By Product, By Test Location, By Technology (PCR, Sequencing), By Application (Oncology, Infectious Disease, Genetic Testing), And Segment Forecasts, 2023 - 2030

Report Overview

The India molecular diagnostics market size was valued at USD 934 million in 2022 and is expected to decline at a compounded annual rate of -7.49% from 2023 to 2030. The rising target disease burden, growing geriatric population, and introduction of technologically advanced products are the major factors driving the growth. Furthermore, the region reports an increase in the demand for POC facilities which is driving the industry’s growth. However, high prices of molecular diagnostic tests and poor reimbursement policies in the country are anticipated to restrain the market growth.

The geriatric population is rapidly increasing in India. As per the Government of India National Statistical Office, India’s geriatric population (aged 60 and above) is projected to rise by 41% over the next decade. It is expected to reach 194 million in 2031 from 138 million in 2021. Among the states, Kerala has the highest elderly population, with around 16.5% geriatric population, followed by Tamil Nadu, Himachal Pradesh, Bihar, Uttar Pradesh, and Assam.

Aging has become a substantial risk factor for numerous diseases, including obesity and diabetes, which, in turn, significantly increases the risk of infectious diseases. For example, the geriatric population is more likely to suffer from infectious diseases such as COVID-19 due to decreased immune function, multimorbidity, and physiological changes associated with aging. According to the WHO, until April 2020, around 95% of the deaths were reported among patients 60 years or above. Furthermore, more than 50% of deaths occurred in patients aged 80 years or older. Therefore, the growing aging population is driving the demand for diagnostics and factoring in the market’s growth.

Rapid technological advancements-leading to accurate results, portability, and cost-effectiveness-are expected to be a high-impact rendering driver for India’s molecular diagnostics market. Companies are upgrading their products by implementing new techniques to gain specific and accurate results. Companies such as Sigma Aldrich Corporation and QIAGEN are developing a new range of molecular diagnostic techniques, such as Transcription-Mediated Amplification (TMA) and Loop-Mediated Isothermal Amplification (LAMP), for the diagnosis of tumors. The growing use of multiplex PCR technologies and real-time PCR equipment; e.g., EpiTect Methyl II PCR by QIAGEN for the detection of DNA methylation, is also likely to boost the market during the forecast period.

Moreover, global companies expanded their regional presence and strategically addressed the Indian market by providing cost-efficient COVID-19 diagnostic products amid the pandemic. For instance, in July 2021, Abbott launched a COVID-19 home test kit in India at a price point of around USD 4.07; this strategic pricing enabled it to target the majority of the population in the country.

Product Insights

The reagents segment dominated the India molecular diagnostics market with a revenue share of 65.3% in 2022. This can be attributed to its high adoption in research and clinical settings, coupled with a rise in demand for Point-of-Care (PoC) and OTC & self-test products. Standard reagents help achieve efficient and accurate results. Standardized results, improved efficiency, and cost-effectiveness are anticipated to support market growth.

Some of the key market players that provide reagents are Abbott; Illumina, Inc.; and Roche Diagnostics. The launch of novel reagents has increased exponentially, which can be attributed to the rising demand for PCR reagents. For instance, in March 2021, PCR Biosystems launched IsoFast Bst Polymerase reagents that support rapid amplification of RNA & DNA, which enables faster testing procedures.

The others segment includes services & software programs that are employed to run the instrumentation process and analyze results. This segment includes program interfaces used for operating diagnostic instruments, conducting analysis, and interpreting results. A rise in strategic alliances between IT and diagnostics companies to enhance the efficacy of diagnostic products is anticipated to fuel market growth. For instance, in January 2022, Avesthagen announced a strategic partnership with Wipro, an Indian IT and consulting firm, to develop and commercialize next-generation sequencing panels in the country.

Technology Insights

In 2022, the PCR technology segment held the largest revenue share of over 75%. The technology markets for In Situ Hybridization (ISH) and genetic sequencing are anticipated to experience an increase in demand during the forecast period. The market share for ISH is expected to grow at a CAGR of over 31% during the forecast period, due to an increase in cancer-affected population and the need for early diagnosis.

PCR diagnostics saw a substantial demand amid the COVID-19 pandemic due to public-private partnerships, such as InDx, which addressed the untapped opportunity in the market. This initiative's main objective is to lower the cost of RT-PCR to make it affordable for larger testing of the population. This initiative supports the rapid indigenous production of RT-PCR diagnostic test kits, enabling the production of over 1 million test kits per day. Due to this initiative, within a year, the cost of RT-PCR tests was reduced from USD 10 to USD 7.

Application Insights

The infectious disease segment dominated the market with a revenue share of over 96% in 2022. Molecular diagnostics form the basis of medical diagnosis for all major viral, bacterial, and parasitic infections. Respiratory infection molecular diagnostics have seen an exponential demand post the spread of SARS-CoV-2 infection.

In addition, the growing number of product launches in this segment is also driving the market. For instance, in April 2020, BD announced the launch of the SARS-CoV-2 test on its BD MAX System. An increased rate of automation along with the ability to process a higher number of samples is expected to drive the demand for molecular diagnostic reagents and consumables, accelerating the market growth.

Oncology also holds one of the largest shares in the applications segment. The increasing incidence of cancer is a key factor driving the market growth. Furthermore, the dynamic fields of oncology research and cancer drug discovery have significant advantages in performing molecular diagnosis using specific biomarkers about major cancer-causing genes & their manifestations. Early identification of predictive biomarkers in molecular diagnosis provides opportunities for early diagnosis of cancer-affected patients and helps develop specifically tailored medication for treatment.

Test Location Insights

The central laboratories segment held the dominant revenue share of over 88% in 2022 and is anticipated to maintain its leading share in the forthcoming years, owing to the high market penetration and procedure volumes. An increase in the number of initiatives undertaken by governments to provide various services, such as reimbursement for diagnostic tests, is another major factor anticipated to drive the market.

However, the self-testing or OTC segment is likely to be the fastest-growing segment over the forecast period. Self-testing in molecular diagnostics has been gaining a lot of interest in recent years. It assists in early diagnosis & constant patient monitoring. In addition, self-test diagnostics aid in curbing costs associated with healthcare establishments and practitioners. With the increasing demand for molecular diagnosis, there is a growing need for PoC products that can assist a patient in conducting self-tests.

A few of the home diagnostic tests are the Home Access Express HIV-1 Test & Home Access Hepatitis C Test developed by Home Access Health Corp., and the ADEXUSDx HIV 1/2 Test developed by NOWDiagnostics. In addition, the increased focus of the regulatory bodies on self-test or OTC molecular diagnostics to lower the burden on laboratories is boosting segment growth.

Key Companies & Market Share Insights

Some of the key players are undertaking strategic initiatives such as new launches, facility expansions, collaborations, and mergers & acquisitions, which are further driving the market growth. For instance, in January 2022, Mylab Discovery Solutions Pvt. Ltd. launched the CoviSwift, a PoC testing solution for COVID-19. This is expected to increase testing capacity from 3000 labs to 60,000 labs in India. Some prominent players in the India molecular diagnostics market include:

• Abbott

• BD (Becton, Dickinson and Company)

• Biomérieux SA

• Bio-Rad Laboratories, Inc.

• Danaher Corporation

• Hologic, Inc.

• Qiagen

• F. Hoffmann-La Roche Ltd.

• Siemens Healthineers

• Sysmex Corporation

• Diasorin S.P.A

• Mylab Discovery Solutions Private Limited

• Biogenix Inc. Pvt. Ltd

• Trivitron Healthcare

• POCT Services Private Limited

India Molecular Diagnostics Market Report Scope

India Molecular Diagnostics Market Segmentation

This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the India molecular diagnostics market report based on product, test location, technology, and application:

• Product Outlook (Revenue, USD Million, 2018 - 2030)

  • Instruments

  • Reagents

  • Others

• Test Location Outlook (Revenue, USD Million, 2018 - 2030)

  • Point-Of-Care (POC)

  • Self-testing or OTC

  • Central Laboratories

• Technology Outlook (Revenue, USD Million, 2018 - 2030)

  • Polymerase chain reaction

  • PCR Market, By Type

    • Multiplex PCR

    • Other PCR

  • PCR Market, By Product

    • Instruments

    • Reagents

    • Others

  • In Situ Hybridization (ISH)

  • Instruments

  • Reagents

  • Others

  • Isothermal Nucleic Acid Amplification Technology (INAAT)

  • Instruments

  • Reagents

  • Others

  • Chips And Microarrays

  • Instruments

  • Reagents

  • Others

  • Mass Spectrometry

  • Instruments

  • Reagents

  • Others

  • Sequencing

  • Instruments

  • Reagents

  • Others

  • Transcription Mediated Amplification (TMA)

  • Instruments

  • Reagents

  • Others

  • Others

  • Instruments

  • Reagents

  • Others

• Application Outlook (Revenue, USD Million, 2018 - 2030)

  • Oncology

  • Breast Cancer

  • Prostate Cancer

  • Colorectal Cancer

  • Cervical Cancer

  • Kidney Cancer

  • Liver Cancer

  • Blood Cancer

  • Lung Cancer

  • Other Cancers

  • Pharmacogenomics

  • Infectious Diseases

    • Methicillin-resistant Staphylococcus Aureus (MRSA)

    • Clostridium difficile

    • Vancomycin-Resistant Enterococci (VRE)

    • Carbapenem-resistant bacteria

    • Flu

    • Respiratory Syncytial Virus (RSV)

    • Candida

    • Tuberculosis (TB) and drug-resistant TBA

    • Meningitis

    • Gastrointestinal Panel Testing

    • Chlamydia

    • Gonorrhea

    • HIV

    • Hepatitis C

    • Hepatitis B

    • Other Infectious Diseases

  • Genetic Testing

    • Newborn Screening

    • Predictive And Presymptomatic Testing

    • Other Genetic Testing

  • Neurological Diseases

  • Cardiovascular diseases

  • Others